A Chinese medicine composition for preventing and treating atherosclerosis and its preparation method and use

Abstract

The present invention belongs to the technical field of traditional Chinese medicine, and specifically relates to a Chinese medicine composition for preventing and treating atherosclerosis, and a preparation method and use thereof. The Chinese medicine composition is made of the following raw materials in parts by weight: 10-50 parts of honeysuckle, 5-20 parts of white peony root, 10-50 parts of hawthorn, 10-50 parts of millettia spatholobi, and 1-20 parts of raw licorice. The Chinese medicine composition of the present invention has the effects of harmonizing blood vessels and clearing turbid toxins. Modern pharmacological experimental results show that the Chinese medicine composition of the present invention has the effects of anti-inflammatory, regulating lipid metabolism, and regulating cell autophagy. In addition, the Chinese medicine composition of the present invention has no damage to the liver and kidneys, has the advantages of good safety, and is suitable for long-term use.

Description

Technical Field

[0001] The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for preventing and treating atherosclerosis, and a preparation method and use thereof. Background Art

[0002] According to the Global Burden of Cardiovascular Disease and Risk Factors 1990-2019, atherosclerotic cardiovascular disease (ASCVD), mainly ischemic heart disease and stroke, is the leading cause of death and disability worldwide, accounting for one-third of the total number of deaths worldwide, with China having the highest incidence of cardiovascular death. The China Cardiovascular Health and Disease Report 2019 shows that ASCVD is the leading cause of death among urban and rural residents in my country, with 45.91% in rural areas and 43.56% in cities. Therefore, ASCVD is a primary public health issue that seriously endangers human health.

[0003] Atherosclerosis (AS) is the main pathological basis of ASCVD. Atherosclerosis is a systemic disease, which is particularly common in the elderly. Its characteristic is that the lesions of the affected arteries start from the intima, generally with the accumulation of lipids and complex carbohydrates, bleeding and thrombosis, followed by fibrosis and calcification, and the gradual degeneration and calcification of the middle layer of the artery, leading to thickening and hardening of the arterial wall and narrowing of the vascular lumen. The lesions often involve large and medium arteries. Once they develop to the point of blocking the arterial lumen, the tissues or organs supplied by the artery will be ischemic or necrotic. Because the lipids accumulated in the intima of the artery appear yellow and porridge-like, it is called atherosclerosis.

[0004] It is generally accepted that lipid deposition and inflammatory response are the key pathological links involved in the formation of AS. However, the results of the CIRT study recently published in the New England Journal of Medicine showed that treatment with the broad-spectrum anti-inflammatory drug methotrexate did not reduce ASCVD mortality. It can be seen that not all drugs with anti-inflammatory effects can be used to prevent and treat AS. Therefore, exploring drug targets that can block specific inflammatory pathways and improving the prevention and treatment of AS can be a breakthrough for future research.

[0005] Traditional Chinese medicine has its unique advantages in treating AS. There are many studies on the use of traditional Chinese medicine to prevent and treat AS, and this field is currently a hot topic of research. According to traditional Chinese medicine, AS can be classified as "blood stasis". The occurrence and development of AS is inseparable from the core pathogenesis of abnormal circulation of qi and blood, and poor blood circulation is the key link of this disease. Traditional Chinese medicine believes that "blood stasis" is the basic pathogenesis of this disease, and promoting blood circulation and removing blood stasis is an important treatment for AS. In addition, traditional Chinese medicine also believes that "qi is the commander of blood, and blood is the mother of qi", and that removing blood stasis also requires regulating qi to achieve the purpose of removing blood stasis and unblocking meridians. However, in clinical practice, it is found that the efficacy of traditional Chinese medicine compositions designed with the treatment principles of simply promoting blood circulation and removing blood stasis, regulating qi and relieving pain in preventing and treating atherosclerosis is not very ideal.

[0006] Therefore, it is still necessary to conduct in-depth research on the pathophysiological mechanisms of atherosclerosis and the interactions between the therapeutic principles of different Chinese herbal compositions for preventing and treating the disease, so as to develop new Chinese herbal compositions for preventing and treating atherosclerosis that are safer, more effective, less expensive and simple to prepare. Summary of the invention

[0007] In order to overcome the problem that the Chinese medicine composition for preventing and treating atherosclerosis based on the treatment principle of "promoting blood circulation and removing blood stasis, promoting qi and relieving pain" in the prior art can only relieve symptoms but not cure the root cause, and has poor efficacy, the present invention takes the lead in adopting the treatment principle of harmonizing blood vessels and clearing turbid toxins, and provides a Chinese medicine composition for preventing and treating atherosclerosis which is simple to prepare, low in cost, has significant efficacy, and has no toxic side effects.

[0008] In the first aspect, the present invention provides a traditional Chinese medicine composition for preventing and treating atherosclerosis, wherein the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10-50 parts of honeysuckle, 5-20 parts of white peony root, 10-50 parts of hawthorn, 10-50 parts of Millettia reticulata, and 1-20 parts of raw licorice.

[0009] As a preferred embodiment, in the above-mentioned traditional Chinese medicine composition, the traditional Chinese medicine composition is made of the following raw materials in parts by weight: 10-40 parts of honeysuckle, 10-20 parts of white peony root, 15-40 parts of hawthorn, 15-40 parts of Millettia reticulata, and 1-10 parts of raw licorice.

[0010] As a preferred embodiment, in the above-mentioned traditional Chinese medicine composition, the traditional Chinese medicine composition is made of the following raw materials in parts by weight: 16-32 parts of honeysuckle, 11-16 parts of white peony root, 21-32 parts of hawthorn, 16-32 parts of Millettia reticulata, and 3-8 parts of raw licorice.

[0011] As a preferred embodiment, in the above-mentioned traditional Chinese medicine composition, the traditional Chinese medicine composition is made of the following raw materials in parts by weight: 32 parts of honeysuckle, 16 parts of white peony root, 32 parts of hawthorn, 32 parts of Millettia reticulata, and 8 parts of raw licorice.

[0012] As a preferred embodiment, in the above-mentioned traditional Chinese medicine composition, the traditional Chinese medicine composition is made of the following raw materials in parts by weight: 16 parts of honeysuckle, 11 parts of white peony root, 21 parts of hawthorn, 16 parts of Millettia reticulata, and 3 parts of raw licorice.

[0013] As a preferred embodiment, in the above-mentioned traditional Chinese medicine composition, the traditional Chinese medicine composition has the effects of harmonizing blood vessels and clearing turbid toxins.

[0014] In a second aspect, the present invention provides use of the Chinese medicine composition described in the first aspect in preparing a medicine.

[0015] As a preferred embodiment, in the above-mentioned use, the use is in a drug for preventing and treating atherosclerosis.

[0016] As a preferred mode, in the above-mentioned use, the drug has the effects of anti-inflammation, regulating lipid metabolism, and regulating cell autophagy.

[0017] As a preferred mode, in the above-mentioned use, the drug has lipid-lowering, fibrinolytic, anticoagulant, antithrombotic and thrombolytic effects.

[0018] As a preferred mode, in the above-mentioned use, the drug is harmless to the liver and kidneys, has the advantages of good safety, and is suitable for long-term use.

[0019] As a preferred mode, in the above use, the drug is in solid form, semi-solid form or liquid form.

[0020] As a preferred mode, in the above-mentioned use, the medicine is a decoction, a decoction, a powder, an oral liquid, an ointment, a granule, a tablet or a capsule.

[0021] As a preferred mode, in the above use, the medicine is a decoction or granules.

[0022] In the third aspect, the drug of the present invention can be prepared by conventional preparation methods in the art, and pharmaceutically acceptable excipients may or may not be added. As long as the Chinese medicine raw material is the above weight portion, regardless of the various changes in its preparation method, it falls within the scope of the present invention. Its drug form includes but is not limited to solid form, semi-solid form or liquid form, etc.; specifically includes but is not limited to decoction pieces, decoctions, powders, oral liquids, pastes, granules, tablets or capsules.

[0023] As a preferred method, the Chinese medicine composition is extracted, such as decoction extraction, reflux extraction, ultrasonic extraction, etc.

[0024] As a preferred method, the method includes weighing each raw material drug, pre-treating, extracting (water and / or alcohol), and concentrating.

[0025] As a preferred method, the process includes weighing each raw material drug, crushing, extracting and concentrating.

[0026] As a preferred embodiment, the extraction method is decoction, and / or the extraction solvent is water or ethanol, and / or the decoction times are 1-3 times, and / or the decoction time for each time is 1-3 hours.

[0027] The formula of the Chinese medicine composition of the present invention is explained as follows:

[0028] In the process of AS, lipid deposition is the initiating factor of AS. In the process of AS development, the thickening of the vascular endothelium and local plaques will form, leading to vascular stenosis. From the perspective of traditional Chinese medicine, the overall pathological process of AS is blood disharmony and endogenous turbid toxins. Blood disharmony leads to weak or poor blood circulation, which may cause vascular stenosis or blockage; endogenous turbid toxins such as phlegm, fat, and heat toxins can further damage local blood vessels, and further damage to blood vessel function can aggravate local blockage.

[0029] Therefore, this prescription is based on harmonizing blood vessels and clearing turbid toxins. Among them, white peony root and Millettia reticulata can harmonize blood vessels without damaging qi and blood. Honeysuckle can clear away heat and detoxify, and can remove blood poisoning evil. Hawthorn can promote qi and disperse blood stasis, remove turbidity and reduce fat. The combination of the two can clear away turbid toxins in the blood. Raw licorice can harmonize various medicines, harmonize blood and detoxify. In summary, the whole prescription can harmonize blood vessels, clear turbid toxins, thereby removing blood stasis and achieving the effect of unblocking blood vessels.

[0030] Honeysuckle is the dried buds or flowers of Lonicera japonica Thunb. of the Caprifoliaceae family. It is sweet and cold, clears away heat and detoxifies, and reduces inflammation and swelling. It is mainly used to treat exogenous wind-heat or fever caused by febrile diseases, heatstroke, heat-toxic bloody diarrhea, carbuncle, furuncle, throat paralysis, and various infectious diseases.

[0031] White Peony is the dried root of Paeonia lactiflora Pall., a plant of the Ranunculaceae family. It is bitter, sour, and slightly cold. It nourishes the blood and softens the liver, relieves pain, and restrains yin and sweat. It is used to treat pain in the chest, abdomen, and ribs, diarrhea, abdominal pain, spontaneous sweating, night sweats, fever due to yin deficiency, irregular menstruation, metrorrhagia, and leukorrhea.

[0032] "Hawthorn" is the dried mature fruit of Crataegus pin,natiida Bge.var.major NEBr. or Crataegus pin.natifida Bge. of the Rosaceae family. It is sour, sweet and slightly warm. It helps digestion and invigorates the stomach, promotes qi and dissipates blood stasis, removes turbidity and reduces fat. It is used for meat stagnation, stomach distension, diarrhea and abdominal pain, blood stasis and amenorrhea, postpartum blood stasis, heart and abdomen stabbing pain, chest pain, hernia pain, and hyperlipidemia. The effect of charred hawthorn on digestion and stagnation is enhanced. It is used for meat stagnation and diarrhea.

[0033] "Chicken blood vine" is the dried vine stem of Spatholobus suberectus Dunn, a plant of the leguminous family. It is bitter, sweet and warm. It has the effects of promoting blood circulation and replenishing blood, regulating menstruation and relieving pain, and relaxing muscles and tendons. It is also effective in treating rheumatic pain, numbness and paralysis, blood deficiency and chlorosis, irregular menstruation, dysmenorrhea, amenorrhea and gynecological diseases.

[0034] Licorice is the dried root and rhizome of Glycyrrhiza uralensis Fisch., Glycyrrhiza inflata Bat. or Glycyrrhiza glabra L. of the leguminous plants. Raw licorice has the effects of clearing away heat and detoxifying, removing phlegm and relieving cough, relieving pain, harmonizing various medicines, treating cramps in the limbs, carbuncles, sores and ulcers.

[0035] Compared with the prior art, the present invention has the following beneficial effects:

[0036] (1) The Chinese medicine composition of the present invention breaks through the traditional treatment methods of promoting blood circulation and removing blood stasis, regulating qi and relieving pain for atherosclerosis, and takes the lead in adopting the treatment methods of harmonizing blood vessels and clearing turbid toxins, which significantly enhances the effect of the Chinese medicine composition in preventing and treating atherosclerosis.

[0037] (2) The results of modern pharmacological experiments show that the Chinese medicine composition of the present invention has the effects of anti-inflammatory, regulating lipid metabolism, and regulating cell autophagy.

[0038] (3) The Chinese medicine composition of the present invention has no damage to the liver and kidneys, has the advantage of good safety, and is suitable for long-term use. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] Figure 1 : Representative photos of the effect of the Chinese medicine composition of the present invention on the results of oil red staining of the aorta (magnification X1).

[0040] Figure 2 : Representative photos of the effect of the Chinese medicine composition of the present invention on HE staining results of aorta (magnification X10).

[0041] Figure 3 : Representative photos (magnification X10) showing the effect of the Chinese medicine composition of the present invention on the MOVAT staining results at the aortic sinus.

[0042] Figure 4 : Representative photos of the immunofluorescence staining results of the Chinese medicine composition of the present invention on the aortic sinus of mice (magnification x10). The order of marking of each group of five pictures in the figure is Merge, DAPI, P62, LAMP2, LC3I / II. DETAILED DESCRIPTION

[0043] The present invention will be further described with reference to specific embodiments below. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the scope of the present invention.

[0044] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.

[0045] The experimental methods in the following examples are conventional methods unless otherwise specified. The experimental materials used in the following examples are commercially available products unless otherwise specified.

[0046] Preparation Example:

[0047] Embodiment 1:

[0048] Honeysuckle 32g, white peony root 16g, hawthorn 32g, Millettia reticulata 32g, raw licorice 8g

[0049] Total quantity: 120g

[0050] Each drug was crushed into fine powder, decocted with 1000 mL of distilled water, filtered after 1.5 hours of first decoction to obtain a primary filtrate, and the residue was decocted with 1000 mL of distilled water for 1.5 hours, filtered to obtain a secondary filtrate, the primary filtrate and the secondary filtrate were combined and concentrated under reduced pressure to obtain 250 mL of concentrated solution.

[0051] Embodiment 2:

[0052] Honeysuckle 16g, white peony root 11g, hawthorn 21g, Millettia reticulata 16g, raw licorice 3g

[0053] Total quantity: 67g

[0054] The preparation method is the same as Example 1.

[0055] Comparative Example 1:

[0056] Honeysuckle 16g, white peony root 11g, hawthorn 37g, raw licorice 3g

[0057] Total quantity: 67g

[0058] The preparation method is the same as Example 1.

[0059] Comparative Example 2:

[0060] Honeysuckle 16g, white peony root 11g, hawthorn 21g, salvia miltiorrhiza 16g, raw licorice 3g

[0061] Total quantity: 67g

[0062] The preparation method is the same as Example 1.

[0063] Comparative Example 3:

[0064] Hawthorn 38g, Millettia reticulata 38g

[0065] Total quantity: 76g

[0066] The preparation method is the same as Example 1.

[0067] Comparative Example 4:

[0068] Forsythia suspensa 16g, white peony root 11g, hawthorn 21g, Millettia reticulata 16g, raw licorice 3g

[0069] Total quantity: 67g

[0070] The preparation method is the same as Example 1.

[0071] Comparative Example 5:

[0072] Honeysuckle 47g, white peony root 32g, raw licorice 9g

[0073] Total quantity: 88g

[0074] The preparation method is the same as Example 1.

[0075] Positive drug group:

[0076] Shenqi Roumai Mixture: Honeysuckle 20g, white peony 15g, processed Polygonum multiflorum 20g, hawthorn 20g, raw licorice 10g, ginseng 10g, astragalus 20g, raw rehmannia 15g, chuanxiong 15g, rhubarb 6g, cassia twig 8g, pinellia 12g, dandelion 20g.

[0077] The preparation method is the same as Example 1.

[0078] Effect Example: Pharmacodynamic Study on the Chinese Medicine Composition of the Present Invention for Preventing and Treating Atherosclerosis

[0079] 1. Preparation for establishing an animal model of atherosclerosis:

[0080] 8-week-old SPF male C57BL / 6J mice, ApoE - / -Mice, weighing (22±2) g, were purchased from Beijing Speywood Biotechnology Co., Ltd., with the animal production license number: SCXK (Beijing) 2019-0010. They were housed in the animal experiment center of Beijing Leweiyuan Medical Technology Co., Ltd., with the license number: SYXK (Beijing) 2022-0007, at a temperature of (22±2) °C and a humidity of (50±10)%, with a 12 h light / dark cycle. The animals had free access to food and water. The animal ethics review batch number: No. SYXK2022-0007. High-fat diet (83.5% basal diet + 15% lard + 1.5% cholesterol) and normal diet were both provided by Beijing Huafukang Biotechnology Co., Ltd. (license number: SCXK (Beijing) 2019-0008).

[0081] 2. Modeling, grouping and administration of animals

[0082] After 1 week of adaptive feeding, 13 C57BL / 6J mice were used as the control group and were fed with normal maintenance diet throughout the experiment. 93 ApoE - / - mice were fed with high-fat diet. After 8 weeks of modeling, 3 mice were randomly selected from the control group and the model group for sampling. HE staining of the aortic sinus pathological sections showed that the aortic intima of the mice in the model group was significantly thickened, and obvious plaque formation was visible, indicating that the in vivo model of AS was successfully established.

[0083] The ApoE mice after modeling - / - were randomly divided into 9 groups: model group, Example 1 group, Example 2 group, Comparative Example 1 group, Comparative Example 2 group, Comparative Example 3 group, Comparative Example 4 group, Comparative Example 5 group, positive drug group, with 10 mice in each group, and continued to be fed with high-fat diet. Except for the model group, while the mice in all drug treatment groups were fed with high-fat diet, they were given corresponding drugs by gavage (at 0.2 ml / rat / day); the control group and the model group were given an equal volume of normal saline by gavage to ensure consistency between groups. Gavage was performed once a day for 8 consecutive weeks. The specific intervention measures are shown in Table 1 below:

[0084] Table 1: Drug administration scheme used in this experiment

[0085]

[0086]

[0087] Note: The drug administration dose was based on the clinically recommended dose of oral administration for 70 kg adults per day and was converted into the gavage dose for mice according to the body surface area conversion coefficient between adults and mice. (References: [1] Xu Shuyun, Pharmacological Experiment Methodology. Anhui Province, Anhui Medical University, 2002-01-01. [2] Zhao Wei, Sun Guozhi. Conversion of drug dosage among different species of experimental animals [J]. Animal Husbandry and Veterinary Science & Technology Information, 2010(05):52-53.)

[0088] 3. Serum and tissue specimen collection

[0089] After the last administration, fasting and water restriction were performed for 12 hours. Blood was collected from the retrobulbar vein (orbital venous plexus) with 3% sodium pentobarbital under intraperitoneal anesthesia, and the blood was kept at room temperature for 2 hours, centrifuged at 4000r / min and 4℃ for 10 minutes, and the upper serum was separated and frozen at -80℃. After blood collection, the chest and abdominal cavities of the mice were opened, and PBS was fully perfused. The aorta from the root of the aorta to the bifurcation of the common iliac artery was separated as a whole, and the surrounding excess connective tissue and adipose tissue were stripped off, and stored in liquid nitrogen or tissue fixative for subsequent related experiments.

[0090] 4. Effect index test

[0091] (1) Detection of serum lipid levels in mice by enzyme-labeled immunosorbent assay

[0092] The levels of TC, TG, LDL-C and HDL-C in mouse serum were detected by automatic biochemical analyzer.

[0093] (2) ELISA method to detect serum inflammatory factor levels

[0094] According to the instructions of the ELISA kit, the levels of IFN-γ and IL-4 in mouse serum were detected.

[0095] (3) Macroscopic determination of the overall aortic plaque area by Oil Red O staining

[0096] The longitudinal section of the mouse aorta was fixed under an optical microscope, washed with water, stained with Oil Red O, and then the blood vessels were laid flat on a black rubber plate. The blood vessels were quickly photographed and analyzed using Image J software to evaluate the severity of aortic plaques. Relative plaque area (%) = aortic intimal plaque area / total blood vessel area × 100%. (4) Evaluation of mouse aortic sinus pathological morphology by hematoxylin-eosin (HE) staining

[0097] The aorta was fixed with 4% paraformaldehyde and placed in a 4°C refrigerator for 24 h, then embedded in paraffin after gradient dehydration and serially sectioned (5 μm), sealed and photographed after routine HE staining, and the changes in the pathological morphology of the aortic sinus were detected under an optical microscope, and the percentage of plaque area to the intima area was measured and calculated. Plaque area percentage = plaque area / total intima area × 100%.

[0098] (5) Russell-Movat staining to evaluate the composition of mouse aortic sinus plaques

[0099] The aorta was processed by paraffin section with a thickness of 5 μm. Continuous sectioning was performed until the three aortic valves were observed to be completely fused. Ten sections were retained, and the sections were dewaxed and hydrated. The sections were stained with five-color dye solution, dehydrated and sealed, and the changes in the components of the aortic sinus plaque were observed under an optical microscope. After staining, the cell nucleus and elastic fibers were black, proteoglycans were blue, collagen fibers were red, and foam cells were lavender.

[0100] (6) Immunofluorescence evaluation of the expression of LAMP2, P62, and LC3 in the aortic sinus of mice

[0101] Paraffin sections of the aortic sinus were routinely dewaxed, hydrated, and antigen-retrieved, then serum-blocked for 30 min at room temperature, primary antibodies were added and incubated overnight at 4°C, and PBS was rinsed three times (5 min each time). The next day, fluorescent secondary antibodies were added and incubated for 1 h at room temperature in the dark, PBS was rinsed three times (5 min each time), DAPI was added and incubated in the dark for 5 min to counterstain the nuclei, PBS was rinsed four times (5 min each time), and finally the sections were sealed with a quencher containing anti-fluorescence. Fluorescence expression of each protein in the aortic sinus was observed using a fluorescence microscope, and images were collected, and the data were analyzed and processed using Image J.

[0102] 5. Statistical methods

[0103] GraphPad Prism 8.0 was used for statistical analysis and statistical drawing, and the experimental results were expressed as X±s. One-Way ANOVA analysis was used for comparison of means among multiple groups, and P<0.05 indicated statistically significant differences.

[0104] 6. Results

[0105] (1) The gross redness of the aorta

[0106] The results of the macroscopic oil red staining of the aorta showed that both Example 1 and Example 2 groups could reduce the overall plaque area of ​​the aorta, which was better than the control group and the positive drug group. Figure 1 And as shown in Table 1.

[0107] Table 1: Proportion of aortic plaques in mice

[0108]

[0109] *Compared with the control group, P < 0.05; △Compared with the model group, P < 0.05

[0110] (2) HE and MOVAT staining of aorta

[0111] The results of HE staining at the aortic sinus showed that both Example 1 and Example 2 could reduce the plaque area; the results of MOVAT staining at the aortic sinus showed that both Example 1 and Example 2 could improve the plaque composition and increase the plaque stability, which were better than the control group and the positive drug group. Figure 2 , Figure 3 And as shown in Table 2.

[0112] Table 2: Proportion of aortic sinus plaques in mice

[0113]

[0114] *Compared with the control group, P < 0.05; △Compared with the model group, P < 0.05

[0115] (3) Blood lipid levels

[0116] In terms of blood lipid levels, total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were detected. The results show that Example 1 and Example 2 can reduce the levels of TC, TG, and LDL-C in mice, and are significantly better than the control group and the positive drug group in reducing LDL-C (a key indicator for the prognosis of atherosclerosis). The results are shown in Table 3.

[0117] Table 3: Serum lipoprotein levels in mice

[0118]

[0119]

[0120] *P<0.05 compared with the control group; △ Compared with the model group, P<0.05

[0121] (4) Levels of inflammatory factors

[0122] For the detection of inflammatory factors, two types of factors, anti-inflammatory and pro-inflammatory, were focused on. IL-4 is an anti-inflammatory factor, and IFN-γ is a typical pro-inflammatory factor. The results suggest that Example 1 and Example 2 can increase the level of the anti-inflammatory factor IL-4 and reduce the level of the pro-inflammatory factor IFN-γ, and Examples 1 and 2 are superior to the positive drug group in increasing the level of anti-inflammatory factors. The results are shown in Table 4.

[0123] Table 4: Levels of inflammatory factors in mouse serum

[0124]

[0125]

[0126] *Compared with the control group, P < 0.05; △Compared with the model group, P < 0.05

[0127] (5) Immunofluorescence results

[0128] Autophagy plays an important role in atherosclerosis. Moderate autophagy can promote the clearance of plaque cells and stabilize atherosclerotic plaques. By detecting LAMP2 (increased levels indicate increased autophagy levels), P62 (decreased levels indicate increased autophagy levels), and LC3I / II (increased levels indicate increased autophagy levels), it was found that Example 1 and Example 2 can significantly promote autophagy in plaques and improve the plaque microenvironment. The results are as follows Figure 4 As shown in Table 5 , the order of marking of each group of five images in the figure is Merge, DAPI, P62, LAMP2, and LC3I / II.

[0129] Table 5: Relative fluorescence intensity of LAMP2, P62, and LC3I / II

[0130]

[0131]

[0132] *Compared with the control group, P < 0.05; △Compared with the model group, P < 0.05

[0133] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.

Claims

1. A Chinese medicine composition for preventing and treating atherosclerosis, characterized in that: The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10-50 parts of honeysuckle, 5-20 parts of white peony root, 10-50 parts of hawthorn, 10-50 parts of millettia reticulata, and 1-20 parts of raw liquorice.

2. The Chinese medicine composition according to claim 1, characterized in that: The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10-40 parts of honeysuckle, 10-20 parts of white peony root, 15-40 parts of hawthorn, 15-40 parts of millettia reticulata, and 1-10 parts of raw licorice.

3. The Chinese medicine composition according to claim 2, characterized in that: The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 16-32 parts of honeysuckle, 11-16 parts of white peony root, 21-32 parts of hawthorn, 16-32 parts of millettia reticulata, and 3-8 parts of raw licorice.

4. The Chinese medicine composition according to claim 3, characterized in that: The Chinese medicine composition is prepared from the following raw materials in parts by weight: 32 parts of honeysuckle, 16 parts of white peony root, 32 parts of hawthorn, 32 parts of millettia reticulata, and 8 parts of raw liquorice; Or the Chinese medicine composition is made of the following raw materials in parts by weight: 16 parts of honeysuckle, 11 parts of white peony root, 21 parts of hawthorn, 16 parts of Millettia reticulata, and 3 parts of raw licorice.

5. The method for preparing the Chinese medicine composition according to any one of claims 1 to 4, characterized in that: The preparation method comprises the following steps: weighing each raw material drug, pre-treating, extracting and concentrating.

6. Use of the Chinese medicine composition according to any one of claims 1 to 4 or the Chinese medicine composition prepared by the preparation method according to claim 5 in preparing a drug for preventing and treating atherosclerosis.

7. The use according to claim 6, characterized in that: The medicine has the effects of regulating blood vessels and clearing away turbid toxins.

8. The use according to claim 6, characterized in that: The drug is in solid form, semi-solid form or liquid form.

9. The use according to claim 8, characterized in that: The medicine is in the form of decoction, powder, oral liquid, paste, granule, tablet or capsule.

10. The use according to claim 9, characterized in that: The medicine is in the form of decoction or granules.

Images